ClinicalTrials.gg
RecruitingNCT06922994SEARCHUpdated Oct 26, 2026

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

A Phase 2 interventional study of Atorvastatin 80 mg/day and Placebo atorvastatin in Arrhythmogenic Cardiomyopathy, sponsored by Centro Cardiologico Monzino. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centro Cardiologico Monzino · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if Atorvastatin 80 mg is effective to avoid functional right ventricular deterioration in patients affected by Arrhythmogenic Cardiomyopathy. It will also learn about the safety of Atorvastatin 80 mg in this type of patients. The main questions it aims to answer are:

  1. Does Atorvastatin 80 mg prevent worstening of the right ventricular functioning?
  2. Does Atorvastatin 80 mg prevent the worsening of electric, morphological and biomarkers deterioration?
  3. What medical problems do participants have when taking Atorvastatin 80 mg?

Researchers will compare Atorvastatin 80 mg to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat Arrhythmogenic Cardiomyopathy.

Participants will:

  1. Take Atorvastatin 80 mg or a placebo every day for 18 months;
  2. Visit the clinic at the enrollment and after 2, 4, 9 and 18 months for checkups and tests;
  3. Make a phone call for safety check after 12, 15 and 19 months since the enrollment;
  4. Fill out psychological questionnaires
02

Conditions studied

  • Arrhythmogenic Cardiomyopathy

Keywords

  • Atorvastatin
  • Strain
  • Disease progression risk
  • Arrhythmias
03

In context

Sprains and Strains

246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.

This study's planned enrollment of 102 is above the median of 60 across 162 interventional studies indexed under Sprains and Strains.

Browse Sprains and Strains studies →

Lead sponsor

Centro Cardiologico Monzino is the lead sponsor of 72 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be at least 18 years of age, at the time of signing the
  2. Participants affected by Arrhythmogenic Cardiomyopathy as defined by task force criteria

Exclusion criteria

Exclusion Criteria:

  1. Known to atorvastatin or any of the
  2. Moderate or severe liver disease
  3. Muscle disease
  4. \<35%
  5. Congestive heart failure defined by the (NYHA) as class III or IV.
  6. Known cardiomyopathy of other origin: post ischemic, hypertrophic, idiopathic dilated, restrictive; known moderate-to-severe mitral or aortic valvulopathy; pulmonary hypertension; congenital cardiac abnormalities
  7. Hypercholesterolemic patients that require the use of lipid lowering drugs.
  8. Heart transplantation
  9. Estimated of less than 2 years
  10. Any other medical condition that, in the judgment of the investigator, places the patient at risk or makes the patient unreliable or limits the patient's ability to complete the study
  11. Potent modifiers such as Erythromycin, Clarithromycin Azole antifungals, Protease inhibitors , Gemfibrozil, Ciclosporin, Danazol
  12. Fusidic acid (drug for bacterial infections)
  13. antivirals as telaprevir, boceprevir, glecaprevir/pibrentasvir and ledipasvir/sofosbuvir combination
  14. Any other lipid lowering drugs such as Statins, Cholesterol absorption inhibitors, Bile acid sequestrants , PCSK9 inhibitors, Adenosine triphosphate-citrate lyase inhibitors , Fibrates, Omega-3 fatty acid ethyl esters
  15. Drugs primary indicated as antioxidants
  16. Enrollment in another clinical trial or past clinical trial in which an drug was administered within 30 days of Visit 1 or within the 5 half-lives of the investigational drug, whichever is longer.
  17. Pregnant or lactating women
  18. Women of childbearing age who are not using adequate
  19. Known dependency on alcohol - drug abuse.
  20. to cardiac magnetic resonance
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    Atorvastatin

    Atorvastatin arm will be composed by 51 patients affected by Arrhythmogenic Cardiomyopathy.

    Drug: Atorvastatin 80 mg/day

  • Placebo comparator
    Placebo

    Placebo arm will be composed by 51 patients affected by Arrhythmogenic Cardiomyopathy.

    Drug: Placebo atorvastatin

Interventions

  • DrugAtorvastatin 80 mg/day

    Drug page: AtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atorvastatin 80mg/day will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy

  • DrugPlacebo atorvastatin

    One tablet of placebo will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy

06

What researchers measure

Primary outcomes

  1. Efficacy of Atorvastatin in avoiding functional right ventricular deterioration

    Variation of right ventricular free wall longitudinal strain measured by echocardiography after 18 months respect to baseline (%)

    Time frame: From enrollment to the end of treatment at 18 months

Secondary outcomes

  1. Safety of Atorvastatin treatment

    Monitoring of adverse events and patient's well-being.

    Time frame: From enrollment to 1 month after the end of treatment (19 months)

  2. Efficacy of Atorvastatin in avoiding morphological deterioration (ventricular volumes)

    Deterioration from baseline of other morphological parameters measured both at echocardiography and cardiac magnetic resonance: ventricular volumes (ml)

    Time frame: From enrollment to the end of treatment (18 months)

  3. Efficacy of Atorvastatin in avoiding morphological deterioration (wall thickness )

    Deterioration from baseline of other morphological parameters measured both at echocardiography and cardiac magnetic resonance: wall thickness (mm)

    Time frame: From enrollment to the end of treatment (18 months)

  4. Efficacy of Atorvastatin in avoiding morphological deterioration (cardiac function )

    Deterioration from baseline of other morphological parameters measured both at echocardiography and cardiac magnetic resonance: cardiac function (%)

    Time frame: From enrollment to the end of treatment (18 months)

  5. Efficacy of Atorvastatin in avoiding arrhythmic deterioration (premature ventricular contractions)

    Deterioration from baseline of arrhythmia burden: premature ventricular contractions (number in the 24h)

    Time frame: From enrollment to the end of treatment at 18 months

  6. Efficacy of Atorvastatin in avoiding arrhythmic deterioration (nonsustained ventricular arrhythmias)

    Deterioration from baseline of arrhythmia burden: nonsustained ventricular arrhythmias (number)

    Time frame: From enrollment to the end of treatment at 18 months

  7. Efficacy of Atorvastatin in avoiding arrhythmic deterioration (sustained ventricular arrhythmias)

    Deterioration from baseline of arrhythmia burden: sustained ventricular arrhythmias (number)

    Time frame: From enrollment to the end of treatment at 18 months

  8. Efficacy of Atorvastatin in avoiding arrhythmic deterioration (ventricular fibrillation )

    Deterioration from baseline of arrhythmia burden: ventricular fibrillation (number)

    Time frame: From enrollment to the end of treatment at 18 months

  9. Efficacy of Atorvastatin in avoiding arrhythmic deterioration (ICD shocks)

    Deterioration from baseline of arrhythmia burden: appropriate ICD shocks (number)

    Time frame: From enrollment to the end of treatment at 18 months

  10. Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (QRS)

    Deterioration from baseline of electrocardiographic parameters: QRS duration (ms)

    Time frame: From enrollment to the end of treatment (18 months)

  11. Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (QT)

    Deterioration from baseline of electrocardiographic parameters: QT duration (ms)

    Time frame: From enrollment to the end of treatment (18 months)

  12. Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (PR)

    Deterioration from baseline of electrocardiographic parameters: PR duration (ms)

    Time frame: From enrollment to the end of treatment (18 months)

  13. Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (amplitudes)

    Deterioration from baseline of electrocardiographic parameters: amplitude of the potential (mV)

    Time frame: From enrollment to the end of treatment (18 months)

  14. Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (T wave)

    Deterioration from baseline of electrocardiographic parameters: ), T wave inversion (number of presences in V1-V6)

    Time frame: From enrollment to the end of treatment (18 months)

  15. Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (ԑ wave)

    Deterioration from baseline of electrocardiographic parameters: ԑ wave in V1-V3 (presence)

    Time frame: From enrollment to the end of treatment (18 months)

  16. Efficacy of Atorvastatin in avoiding biomarkers deterioration (oxLDL)

    Deterioration from baseline of blood parameters: oxLDL (mU/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  17. Efficacy of Atorvastatin in avoiding biomarkers deterioration (MDA)

    Deterioration from baseline of blood parameters: MDA (ng/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  18. Efficacy of Atorvastatin in avoiding biomarkers deterioration (4HNE)

    Deterioration from baseline of blood parameters: 4HNE (pg/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  19. Efficacy of Atorvastatin in avoiding biomarkers deterioration (estradiol)

    Deterioration from baseline of blood parameters: estradiol (pg/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  20. Efficacy of Atorvastatin in avoiding biomarkers deterioration (testosterone)

    Deterioration from baseline of blood parameters: testosterone (ng/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  21. Efficacy of Atorvastatin in avoiding biomarkers deterioration (BIN1)

    Deterioration from baseline of blood parameters: BIN1 (pg/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  22. Efficacy of Atorvastatin in avoiding biomarkers deterioration (GAL3)

    Deterioration from baseline of blood parameters: GAL3 (ng/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  23. Efficacy of Atorvastatin in avoiding biomarkers deterioration (HSP70)

    Deterioration from baseline of blood parameters: HSP70 (ng/mL)

    Time frame: From enrollment to the end of treatment (18 months)

  24. Efficacy of Atorvastatin in avoiding biomarkers deterioration (TGFb)

    Deterioration from baseline of blood parameters: TGFb (pg/mL)

    Time frame: From enrollment to the end of treatment (18 months)

  25. Efficacy of Atorvastatin in avoiding biomarkers deterioration (ST2)

    Deterioration from baseline of blood parameters: ST2 (ng/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  26. Efficacy of Atorvastatin in avoiding biomarkers deterioration (BNP)

    Deterioration from baseline of blood parameters: BNP (pg/mL)

    Time frame: From enrollment to the end of treatment (18 months)

  27. Efficacy of Atorvastatin in avoiding biomarkers deterioration (NTproBNP)

    Deterioration from baseline of blood parameters: NTproBNP (pg/mL)

    Time frame: From enrollment to the end of treatment (18 months)

  28. Efficacy of Atorvastatin in avoiding biomarkers deterioration (hs-cTnI)

    Deterioration from baseline of blood parameters: hs-cTnI (ng/L)

    Time frame: From enrollment to the end of treatment (18 months)

  29. Efficacy of Atorvastatin in avoiding biomarkers deterioration (CRP)

    Deterioration from baseline of blood parameters: CRP (mg/L)

    Time frame: From enrollment to the end of treatment (18 months)

  30. Efficacy of Atorvastatin in avoiding biomarkers deterioration (IL6)

    Deterioration from baseline of blood parameters: IL6 (pg/ml)

    Time frame: From enrollment to the end of treatment (18 months)

  31. Efficacy of Atorvastatin in avoiding biomarkers deterioration (TNF alfa)

    Deterioration from baseline of blood parameters: TNF alfa (pg/ml)

    Time frame: From enrollment to the end of treatment (18 months)

07

Study locations

4 of 5 sites recruiting
08

References and documents

Publications

  • Sommariva E, Stadiotti I, Casella M, Catto V, Dello Russo A, Carbucicchio C, Arnaboldi L, De Metrio S, Milano G, Scopece A, Casaburo M, Andreini D, Mushtaq S, Conte E, Chiesa M, Birchmeier W, Cogliati E, Paolin A, Konig E, Meraviglia V, De Musso M, Volani C, Cattelan G, Rauhe W, Turnu L, Porro B, Pedrazzini M, Camera M, Corsini A, Tondo C, Rossini A, Pompilio G. Oxidized LDL-dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy. EMBO Mol Med. 2021 Sep 7;13(9):e14365. doi: 10.15252/emmm.202114365. Epub 2021 Aug 2. PubMed 34337880 ↗
  • Sommariva E, Lippi M, Bruttini F, Cannata F, Baggiano A, Schiavone M, Salina G, Sabatino M, Vettor G, Sicuso R, Pizzamiglio F, Ribatti V, Maragna R, Carbucicchio C, DeLuca F, Catto V, Iezzi A, Sale EO, Valeri Y, Barbarossa A, Caiazza M, Monda E, Frisso G, Borrelli F, Gasperetti A, Turco A, De Luca L, Corino VDA, Galotta A, Bonomi A, Pompilio G, Pontone G, Muratori M, Limongelli G, Lombardi R, Casella M, Tondo C. Statin effect on arrhythmogenic cardiomyopathy disease progression (SEARCH): Randomized clinical study protocol. PLoS One. 2025 Sep 29;20(9):e0332876. doi: 10.1371/journal.pone.0332876. eCollection 2025. PubMed 41021550 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Nov 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Apr 11, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Dec 30, 2026was Nov 2026
CompletionEst.
Dec 30, 2026was Nov 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Dec 30, 2026
Oct 26, 2026
Study completion
Nov 30, 2026→Dec 30, 2026
Oct 26, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41021550 ↗
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41021550 ↗
    Primary completion Nov 30, 2026→Dec 30, 2026
    Study completion Nov 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06922994
Lead sponsor
Centro Cardiologico Monzino
Collaborators
Federico II University, Università Politecnica delle Marche, Ospedali dei Colli
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Mar 31, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Elena Sommariva
Contact
elena.sommariva@cardiologicomonzino.it
+39 0258002752
Claudio Tondo
Contact
claudio.tondo@cardiologicomonzino.it
+39 0258002275
Claudio Tondo
principal investigator · Centro Cardiologico Monzino IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion